Galectin Therapeutics Inc. (GALT)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Galectin Therapeutics Inc. (GALT) is down 25.0% since the beginning of the year. At $3 per share, GALT is trading 56.2% below its 52-week high of $7. Investors who bought $1,000 worth of GALT shares 5 years ago would now be looking at an investment worth $912.

Galectin Therapeutics Inc. (GALT) has returned -25.00% so far this year and 25.81% over the past 12 months. Over the last ten years, GALT has returned 7.25% per year, falling short of the S&P 500 Index benchmark, which averaged 13.71% annually.

Based on dividend-adjusted daily data since Sep 9, 2002, GALT's average daily return is +0.17%, while the average monthly return is +2.85%. At this rate, an investment would double in approximately 2.1 years.

Historically, 47% of months were positive and 53% were negative. The best month was Feb 2007 with a return of +313.8%, while the worst month was Jun 2007 at -58.8%. The longest winning streak lasted 6 consecutive months, and the longest losing streak was 9 months.

On a daily basis, GALT closed higher 43% of trading days. The best single day was Jan 10, 2014 with a return of +78.3%, while the worst single day was Jul 29, 2014 at -60.8%.

Galectin Therapeutics Inc. has an annualized alpha of 43.93%, beta of 0.57, and R2 of 0.01 versus S&P 500 Index. Calculated based on daily prices since September 09, 2002.

• This stock participated in 130.00% of S&P 500 Index downside but only 55.74% of its upside - more exposed to losses than it benefited from rallies.
• Beta of 0.57 may look defensive, but with R2 of 0.01 this stock is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
• R2 of 0.01 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

GALT ranks 53 for risk / return — on par with similar stocks. You're getting a typical balance of risk and reward. Not a standout, but not a red flag either — a reasonable choice if other factors align with your goals.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Galectin Therapeutics Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Galectin Therapeutics Inc. was 99.02%, occurring on Nov 17, 2008. The portfolio has not yet recovered.

The current Galectin Therapeutics Inc. drawdown is 91.53%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Galectin Therapeutics Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Galectin Therapeutics Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.